Media ReleasesImmutep

View All Immutep News


Immutep receives A$3.4 million R&D tax incentive from French Government


Immutep Limited (ASX:IMM; NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce it has received a 2,126,617 euros (~A$3,430,952) research and development (R&D) tax incentive payment in cash from the French Government under its Credit d'Impot Recherche scheme (CIR).

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.